Investigation of the role of tumour necrosis factor-α, interleukin-1β, interleukin-10, nitric oxide and rheumatoid factor-immunoglobulin M in a rat model of arthritis

Laboratory Animals

Volumn 44, Issue 2, 2010, Pages 143-149

  Khalifeh, M S ^a   Al Rukibat, R ^a   Hananeh, W ^a   Boumezrag, A ^a   Okour, O ^a  

^a JORDAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Jordan)

Author keywords

Collagen induced arthritis; IL 1 ; IL 10; N acetylmuramyl dipeptide; Nitric oxide; Rheumatoid factor IgM; TNF

Indexed keywords

AUTOANTIBODY; IMMUNOGLOBULIN M; INTERLEUKIN 10; INTERLEUKIN 1BETA; NITRIC OXIDE; RHEUMATOID FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST; IMMUNOPATHOLOGY; MALE; NONHUMAN; PROTEIN FUNCTION; RAT; RHEUMATOID ARTHRITIS; SPRAGUE DAWLEY RAT; TH1 CELL; TH2 CELL;

ANIMALS; ARTHRITIS, RHEUMATOID; DISEASE MODELS, ANIMAL; IMMUNOGLOBULIN M; INTERLEUKIN-10; INTERLEUKIN-1BETA; MALE; NITRIC OXIDE; RATS; RATS, SPRAGUE-DAWLEY; RHEUMATOID FACTOR; TH1 CELLS; TUMOR NECROSIS FACTOR-ALPHA;

ANIMALIA; RATTUS;

EID: 77950789970     PISSN: 00236772     EISSN: None     Source Type: Journal    
DOI: 10.1258/la.2009.0080132     Document Type: Article

References (39)

1. Wernhoff P, Olofsson P, Holmdahl R. The genetic control of rheumatoid factor production in a rat model of rheumatoid arthritis. Arthritis Rheum 2003;48:3584-96. (Pubitemid 37531926)
2. Kageyama Y, Miyamoto S, Ozeki T, Hiyohsi M, Suzuki M, Nagano A. Levels of rheumatoid factor isotypes, metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 in synovial fluid from various arthritides. Clin Rheumatol 2000;19:14-20. (Pubitemid 30123235)
3. Chang JM, Cheng CM, Hung LM, Chung YS, Wu RY. Potential use of Plectranthus amboinicus in the treatment of rheumatoid arthritis. Evid Based Complement Altern Med 2007, Nov 23, nem 168.
4. Bas S, Perneger TV, Seitz M, Tiercy JM, Roux-Lombard P, Guerne PA. Diagnostic tests for rheumatoid arthritis: comparison of anti-cyclic citrullinated peptide antibodies, anti-keratin antibodies and IgM rheumatoid factors. Rheumatology (Oxf) 2002;41:809-14. (Pubitemid 34822965)
5. Khalifeh MS, Hananeh W, Al-Rukibat R, Okour O, Boumezrag A. Clinical and histopathological evaluation of MDP/collagen induced arthritis rat model (MCIA) after treatment with Urtica dioica, Plantago major and Hypericum perforatum L herbal mixture. Exp Anim 2008;57:101-10. (Pubitemid 351959506)
6. Williams DG, Moyes SP, Mageed RA. Rheumatoid factor isotype switch and somatic mutation variants within rheumatoid arthritis synovium. Immunology 1999;98:123-36.
7. Williams RO. Collagen-induced arthritis in mice. Methods Mol Med 2007;136:191-9.
8. McGuirk P, Mills KHG. Pathogen-specific regulatory T cells provoke a shift in the Th-1/Th-2 paradigm in immunity to infectious diseases. Trends Immunol 2002;23:450-5.
9. Joosten L, Helsen M, Saxne T, Heinega D, van de Putte LB, van den Berg WB. Synergistic protection against cartilage destruction by low dose prednisolone and interleukin-10 in established murine collagen arthritis. Inflamm Res 1999;48:48-55. (Pubitemid 29050276)
10. McCartney-Francis N, Allen JB, Mizel DE, et al. Suppression of arthritis by an inhibitor of nitric oxide synthase. J Exp Med 1993;178:749-54. (Pubitemid 23218226)
11. Stefanovic-Racic M, Meyers K, Meschter C, Coffey JW, Hoffman RA, Evans CH. Comparison of the nitric oxide synthase inhibitors methylarginine and aminoguanidine as prophylactic and therapeutic agents in rat adjuvant arthritis. J Rheumatol 1995;22:1922-8.
12. St Clair EW, Wilkinson WE, Lang T, et al. Increased expression of blood mononuclear cell nitric oxide synthase type 2 in rheumatoid arthritis patients. J Exp Med 1996;184:1173-8. (Pubitemid 26313575)
13. da S Rocha JC, Peixoto ME, Jancar S, de Q Cunha F, de A Ribeiro R, da Rocha FA. Dual effect of nitric oxide in articular inflammatory pain in zymosan-induced arthritis in rats. Br J Pharmacol 2002;136:588-96. (Pubitemid 34717703)
14. Institute of Laboratory Animal Resources (US). Guide for the Care and Use of Laboratory Animals. Washington, DC: Institute of Laboratory Animal Resources, 1996:v.
15. Morton DB, Griffiths PH. Guidelines on the recognition of pain, distress and discomfort in experimental animals and an hypothesis for assessment. Vet Rec 1985;116:431-6.
16. Danneman PJ, Stein S, Walshaw SO. Humane and practical implications of using carbon dioxide mixed with oxygen for anesthesia or euthanasia of rats. Lab Anim Sci 1997;47:376-85. (Pubitemid 127520673)
17. Marty I, Peclat V, Kirdaite G, Salvi R, So A, Busso N. Amelioration of collagen-induced arthritis by thrombin inhibition. J Clin Invest 2001;107:631-40. (Pubitemid 32205184)
18. Semble EL. Rheumatoid arthritis: new approaches for its evaluation and management. Arch Phys Med Rehabil 1995;76:190-201.
19. Strand V, Kavanaugh AF. The role of interleukin-1 in bone resorption in rheumatoid arthritis. Rheumatology (Oxf) 2004;43 (Suppl 3):iii10-16.
20. Dayer JM. The saga of the discovery of IL-1 and TNF and their specific inhibitors in the pathogenesis and treatment of rheumatoid arthritis. Joint Bone Spine 2002;69:123-32.
21. Joosten LA, Helsen MM, van de Loo FA, van den Berg WB. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNF alpha, anti-IL-1 alpha/beta, and IL-1RA. Arthritis Rheum 1996;39:797-809. (Pubitemid 26140426)
22. Magari K, Miyata S, Ohkubo Y, Mutoh S. Inflammatory cytokine levels in paw tissues during development of rat collagen-induced arthritis: effect of FK506, an inhibitor of T cell activation. Inflamm Res 2004;53: 469-74. (Pubitemid 39382170)
23. Mori L, Iselin S, De Libero G, Lesslauer W. Attenuation of collagen-induced arthritis in 55-kDa TNF receptor type 1 (TNFR1)-IgG1-treated and TNFR1-deficient mice. J Immunol 1996;157:3178-82. (Pubitemid 126450081)
24. Li S, Lu A, Li B, Wang Y. Circadian rhythms on hypothalamic- pituitary-adrenal axis hormones and cytokines of collagen induced arthritis in rats. J Autoimmun 2004;22:277-85. (Pubitemid 38543219)
25. Bingham CO III. The pathogenesis of rheumatoid arthritis: pivotal cytokines involved in bone degradation and inflammation. J Rheumatol Suppl 2002;65:3-9.
26. Evans CH, Watkins SC, Stefanovic-Racic M. Nitric oxide and cartilage metabolism. Methods Enzymol 1996;269:75-88. (Pubitemid 26295698)
27. Farrell AJ, Blake DR, Palmer RM, Moncada S. Increased concentrations of nitrite in synovial fluid and serum samples suggest increased nitric oxide synthesis in rheumatic diseases. Ann Rheum Dis 1992;51: 1219-22.
28. Grabowski PS, England AJ, Dykhuizen R, et al. Elevated nitric oxide production in rheumatoid arthritis. Detection using the fasting urinary nitrate:creatinine ratio. Arthritis Rheum 1996;39:643-7. (Pubitemid 26118043)
29. McInnes IB, Leung BP, Field M, et al. Production of nitric oxide in the synovial membrane of rheumatoid and osteoarthritis patients. J Exp Med 1996;184:1519-24. (Pubitemid 26354707)
30. Ueki Y, Miyake S, Tominaga Y, Eguchi K. Increased nitric oxide levels in patients with rheumatoid arthritis. J Rheumatol 1996;23:230-6. (Pubitemid 26078379)
31. Hersmann GH, Kriegsmann J, Simon J, Huttich C, Brauer R. Expression of cell adhesion molecules and cytokines in murine antigen-induced arthritis. Cell Adhes Commun 1998;6:69-82. (Pubitemid 28451387)
32. Zhou R, Zheng SX, Tang W, et al. Inhibition of inducible nitric-oxide synthase expression by (5R)-5-hydroxytriptolide in interferon-gammaand bacterial lipopolysaccharide-stimulated macrophages. J Pharmacol Exp Ther 2006;316:121-8. (Pubitemid 41832588)
33. Chiou WF, Chou CJ, Chen CF. Camptothecin suppresses nitric oxide biosynthesis in raw 264.7 macrophages. Life Sci 2001;69:625-35. (Pubitemid 32673621)
34. Lapadula G, Iannone E, Dell'Accio F, Covelli M, Pipitone V. Interleukin-10 in rheumatoid arthritis. Clin Exp Rheumatol 1995;13: 629-32.
35. Lacki JK, Klama K, Mackiewicz SH, Mackiewicz U, Muller W. Circulating interleukin 10 and interleukin-6 serum levels in rheumatoid arthritis patients treated with methotrexate or gold salts: preliminary report. Inflamm Res 1995;44:24-6.
36. Del Prete G, De Carli M, Almerigogna F, Giudizi MG, Biagiotti R, Romagnani S. Human IL-10 is produced by both type 1 helper (Th-1) and type 2 helper (Th-2) T cell clones and inhibits their antigen-specific proliferation and cytokine production. J Immunol 1993;150:353-60. (Pubitemid 23133609)
37. Keystone E, Wherry J, Grint P. IL-10 as a therapeutic strategy in the treatment of rheumatoid arthritis. Rheum Dis Clin N Am 1998;24:629-39. (Pubitemid 28416813)
38. Bejarano MT, de Waal Malefyt R, Abrams JS, et al. Interleukin 10 inhibits allogeneic proliferative and cytotoxic T cell responses generated in primary mixed lymphocyte cultures. Int Immunol 1992;4:1389-97.
39. William P. Cytokine imbalance in the pathogenesis of rheumatoid arthritis: the role of interleukin-1 receptor antagonist. Semin Arthritis Rheum 2001;30:1-6. (Pubitemid 32467129)